Find and Pitch Jounalists, Get Your Story Covered

Tags: Camber Pharmaceuticals Generic Bentyl Gastrointestinal disorders Gabapentin Oral Solution Generic Neurontin

	Profile	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Merck is broadening its pipeline as Keytruda’s patent cliff looms - 17 days ago Backlash builds against Novo’s Catalent takeover - 3 months ago BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - 6 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 6 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 7 months ago Ahead of its upcoming decision date, a competitor takes aim at KarXT - 7 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Cambridge Cognition highlights positive Cantab results - 23 days ago CatalYm shows potential of visugromab for treating cachexia - about 2 months ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - 25 days ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 5 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 10 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 12 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 12 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - about 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - about 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - about 1 year ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - over 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - over 1 year ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - over 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - over 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - over 1 year ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender - about 1 month ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 5 months ago Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program - 8 months ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - about 2 months ago An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 4 months ago Up-and-comers look for an edge in the bustling ADC field - 7 months ago As BMS announces major cuts, its Karuna deal looks poised to drive growth - 9 months ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - about 1 year ago
6	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer - about 2 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 5 months ago STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 11 months ago STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease - 12 months ago STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion - about 1 year ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 11 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 12 months ago STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug - over 1 year ago
9	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion - 12 months ago STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval - over 1 year ago
10	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study - about 1 year ago STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer - about 1 year ago Why Cerevel Therapeutics has risen 50% in three days without changing anything - about 1 year ago

Journalists covering Camber Pharmaceuticals